Biodistribution studies in EpCAM transgenic mice suggested preferential access of EpCAM-specific mAbs to tumour cells in spite of a background expression of EpCAM on healthy tissue (McLaughlin et al, 2001). Here, EPCAM is linked to neoplasm.